Slowly Progressive Type 1 Diabetes (SPT1D) is characterized by the absence of insulin dependence at the onset of diabetes and persistent detection of islet cell autoantibodies. These patients with high titers of glutamic acid decarboxylase autoantibodies (GADA) are known to progress to insulin dependence within several years. Low-dose insulin injections have been reported to prevent or delay the decline of insulin secretion in SPT1D patients. We experienced the case of an SPT1D patient with preserved endogenous insulin secretion and good glycemic control achieved with α-glucosidase inhibitor (α-GI) treatment alone for 10 years despite having continuously elevated GADA titers. The details of this case suggest that α-GI treatment might have preventive effects on SPT1D progression.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2169/internalmedicine.51.8123 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recent advances in mRNA-based therapeutics for neurodegenerative diseases and brain tumors.
Nanoscale
January 2025
Department of Ultrasound, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Messenger RNA (mRNA) therapy is an innovative approach that delivers specific protein-coding information. By promoting the ribosomal synthesis of target proteins within cells, it supplements functional or antigenic proteins to treat diseases. Unlike traditional gene therapy, mRNA does not need to enter the cell nucleus, reducing the risks associated with gene integration.
View Article and Find Full Text PDFBackground: Type 2 diabetes (T2D) and older age are well-known risk factors for dementia. Indeed, there is evidence that older adults not diagnosed, but at-risk for T2D can show early signs of cognitive decline, further exacerbated by excessive body weight or high blood glucose levels. Such a finding would have implications for early treatment strategies; however, the evidence is still sparse.
View Article and Find Full Text PDFApigenin as an emerging hepatoprotective agent: current status and future perspectives.
Front Pharmacol
December 2024
School of Clinical Medical, Chengdu Medical College, Chengdu, China.
Apigenin (CHO, API) is a natural flavonoid widely found in vegetables, fruits, and plants such as celery, oranges, and chamomile. In recent years, API has attracted considerable attention as a dietary supplement due to its low toxicity, non-mutagenic properties and remarkable therapeutic efficacy in various diseases. In particular, evidence from a large number of preclinical studies suggests that API has promising effects in the prevention and treatment of a variety of liver diseases, including multifactorial liver injury, non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, liver fibrosis and liver cancer.
View Article and Find Full Text PDFBelzutifan as the Primary Treatment of Bilateral Juxtapapillary Retinal Hemangioblastoma in a Patient With Von Hippel-Lindau Disease.
J Vitreoretin Dis
December 2024
Dartmouth Hitchcock Medical Center, Department of Surgery, Ophthalmology Section, Lebanon, NH, USA.
To describe the efficacy of belzutifan as a treatment for juxtapapillary retinal hemangioblastomas in patients with von Hippel-Lindau disease. A case and its findings were analyzed, and a systematic literature review was conducted using PubMed and Ovid MEDLINE. At a routine follow-up, a 63-year-old woman with a history of von Hippel-Lindau disease and slowly progressive bilateral juxtapapillary retinal hemangioblastomas presented with decreased visual acuity (VA) in the right eye resulting from significant lesion growth and an increase in central macular edema and exudate.
View Article and Find Full Text PDFGPLD1+ cancer stem cells contribute to chemotherapy resistance and tumor relapse in intestinal cancer.
J Biochem
January 2025
Laboratory of Anticancer Strategies, Advanced Research Initiative, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan.
Article Synopsis
- Cancer stem cells (CSCs) are crucial in cancer growth and resistance, and recent research has identified GPLD1 as a marker for slowly cycling CSCs using a mouse intestinal cancer model.
- Inhibiting GPLD1, particularly combined with the chemotherapy drug 5-fluorouracil, significantly reduces cancer cell viability and prevents tumor regrowth in organoids.
- The study also reveals the role of GPLD1 in activating Wnt signaling and promoting epithelial-mesenchymal transition (EMT) through the cleavage of serine protease 8 (PRSS8), indicating that targeting GPLD1 could be a promising new treatment approach for colorectal cancer.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!